Min Young Joo, Ahn Jong Joon, Noh Young Ju, Cha Hee Jeong, Suh Jae Hee, Jung Jong Pil, Park Chang Ryul, Jeong Ae Kyung, Park Jae Hoo, Lee Ki Man
Department of Internal Medicine, Radiation Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Korean J Intern Med. 2004 Jun;19(2):109-13. doi: 10.3904/kjim.2004.19.2.109.
The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell lung cancer (NSCLC) patients older than 60 years of age including those with a poor performance status.
Thirty patients received 135 mg/m2 of paclitaxel on day 1, and carboplatin was administered to the patients on day 1 every 4 weeks over an area under the concentration-time curve of 6.
The response rate was 40%, the median overall survival was 9.1 months (95% CI, 4.2 to 14 months), and the 1 year survival rate was 31%. The median progression-free survival was 7.7 months (95% CI, 3.1 to 12.2 months). In addition, the toxicities were generally mild and reversible.
This study demonstrates that a less intensive combination of paclitaxel/carboplatin is active and well tolerated in advanced NSCLC patients who are older than 60 years including those with a poor PS 3-4.
本研究的目的是评估紫杉醇和卡铂较低强度联合方案在60岁以上晚期非小细胞肺癌（NSCLC）患者（包括那些体能状态较差者）中的疗效、生存率和毒性。
30例患者在第1天接受135mg/m²的紫杉醇治疗，卡铂在第1天给药，每4周一次，浓度-时间曲线下面积为6。
缓解率为40%，中位总生存期为9.1个月（95%CI，4.2至14个月），1年生存率为31%。中位无进展生存期为7.7个月（95%CI，3.1至12.2个月）。此外，毒性一般较轻且可逆。
本研究表明，紫杉醇/卡铂较低强度联合方案在60岁以上晚期NSCLC患者（包括PS 3-4较差者）中具有活性且耐受性良好。
